IP Verse

Ipsen Biopharm competitive analysis

Latest publications and patents of Ipsen Biopharm New

Explore the latest publications and patents granted to Ipsen Biopharm, showcasing their recent innovations and technological advancements.

Last updated on: Sep 30, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Ipsen Biopharm

EP3796929
Sep 18, 2024Suppression Of Bone Cancer-Induced AllodyniaGranted And Under Opposition
EP3758611
Jul 24, 2024Use Of Ultrasound To Guide Injection Of Non-Cytotoxic ProteaseGranted And Under Opposition
EP3266456
May 5, 2021Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic CancerGranted And Under Opposition
EP3337467
Dec 9, 2020Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer TreatmentRevoked
EP3337478
Aug 12, 2020Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And OxaliplatinGranted And Under Opposition
EP2939688
Feb 20, 2019Pharmaceutical Compositions Comprising Botulinum NeurotoxinOpposition Rejected
EP2861210
May 3, 2017Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal IrinotecanRevoked

Latest oppositions filed by Ipsen Biopharm

Explore patent oppositions filed by Ipsen Biopharm against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4161562
High Dose And Low Volume Botulinum Toxin Treatment Of Facial WrinklesMERZ PHARMAAug 20, 2025
EP3368071
Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic EffectREVANCE THERAPEUTICSOct 26, 2022
EP3094331
Combination-Based Treatment MethodNEKTAR THERAPEUTICSSep 27, 2018

Latest patents of Ipsen Biopharm opposed by its competitors

Explore Ipsen Biopharm's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3796929
Sep 18, 2024Suppression Of Bone Cancer-Induced Allodynia1
EP3758611
Jul 24, 2024Use Of Ultrasound To Guide Injection Of Non-Cytotoxic Protease1
EP3266456
May 5, 2021Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer3
EP3337467
Dec 9, 2020Combination Therapy Using Liposomal Irinotecan And A Parp Inhibitor For Cancer Treatment1
EP3337478
Aug 12, 2020Methods For Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan And Oxaliplatin2
EP2939688
Feb 20, 2019Pharmaceutical Compositions Comprising Botulinum Neurotoxin1
EP2861210
May 3, 2017Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan1

Latest PTAB cases involving Ipsen Biopharm

Discover the latest PTAB cases involving Ipsen Biopharm, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 6, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Ipsen Biopharm

IPR2025-00505Jan 17, 2025CSPC PHARMACEUTICAL GROUPIPSEN BIOPHARMTrial Instituted

Peer Comparison New

IP litigation analysis comparing Ipsen Biopharm with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
IPSEN BIOPHARM110 - 1Defensive
GENERICS UK212 - - - Highly Aggressive
SANDOZ1141519 - Highly Aggressive
TEVA PHARMACEUTICALS20515 - 12Highly Aggressive